875781-44-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-7-iodo-5H-pyrrolo[2,3-b]pyrazine is used as a building block for the synthesis of various organic compounds, particularly in the development of new drugs. Its unique structure and reactivity make it a valuable intermediate in medicinal chemistry, facilitating the creation of novel pharmaceutical agents with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Bromo-7-iodo-5H-pyrrolo[2,3-b]pyrazine is utilized as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its chemical properties allow for the development of compounds with enhanced efficacy and selectivity in controlling pests and weeds, contributing to more sustainable agricultural practices.
Used in Material Science:
2-Bromo-7-iodo-5H-pyrrolo[2,3-b]pyrazine also finds applications in material science, where it serves as a key component in the synthesis of advanced materials with specific properties. Its incorporation into materials can lead to the development of new polymers, coatings, or other materials with improved characteristics, such as enhanced stability, reactivity, or selectivity in various applications.
Overall, the diverse applications of 2-Bromo-7-iodo-5H-pyrrolo[2,3-b]pyrazine across different industries highlight its versatility and potential as a valuable chemical intermediate. Its unique structure and reactivity contribute to the advancement of research and development in pharmaceuticals, agrochemicals, and material science, paving the way for innovative solutions and products.

InChI:InChI=1S/C6H3BrIN3/c7-4-2-10-6-5(11-4)3(8)1-9-6/h1-2H,(H,9,10)

Upstream product

• 875781-42-3 N-(5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-yl)acetamide 
• 875781-41-2 5-bromo-3-((trimethylsilyl)ethynyl)pyrazine-2-amine 
• 875781-43-4 2-bromo-5H-pyrrolo[2,3-b]pyrazine 

Downstream Products

• 875781-45-6 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[3,2-b]pyrazine 
• 1229583-75-8 2-bromo-7-(1H-indol-5-yl)-5-tosyl-5H-pyrrolo[3,2-b]pyrazine 
• 1229582-37-9 7-(1H-indol-5-yl)-2-(3,4,5-trimethoxyphenyl)-5H-pyrrolo[3,2-b]pyrazine 

Relevant academic research and scientific papers

Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3- b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity

There are currently no approved drugs for the treatment of emerging viral infections, such as dengue and Ebola. Adaptor-associated kinase 1 (AAK1) is a cellular serine-threonine protein kinase that functions as a key regulator of the clathrin-associated host adaptor proteins and regulates the intracellular trafficking of multiple unrelated RNA viruses. Moreover, AAK1 is overexpressed specifically in dengue virus-infected but not bystander cells. Because AAK1 is a promising antiviral drug target, we have embarked on an optimization campaign of a previously identified 7-azaindole analogue, yielding novel pyrrolo[2,3-b]pyridines with high AAK1 affinity. The optimized compounds demonstrate improved activity against dengue virus both in vitro and in human primary dendritic cells and the unrelated Ebola virus. These findings demonstrate that targeting cellular AAK1 may represent a promising broad-spectrum antiviral strategy.

PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES

Disclosed are methods for treating an individual infected with a retrovirus that comprise administering to the individual effective amounts of a mixed lineage kinase inhibitor and antiretroviral drug. In further aspects, disclosed are methods for treating an individual infected with a retrovirus that comprises administering an antiretroviral drug formulated into a crystalline nanoparticle comprising a surfactant, and a MLK inhibitor. Still further disclosed are methods for treating an individual infected with a retrovirus that comprises administering a composition comprising both an antiretroviral and MLK inhibitor formulated into a crystalline nanoparticle, which comprises a surfactant. Still further disclosed are compositions that comprise an antiretroviral drug, a MLK inhibitor, and a surfactant, wherein the composition is a crystalline nanoparticle. Compostions comprising MLK inhibitors with other drugs in nanoparticulate form, and methods of there use, are also disclosed.

BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE

Provided are compounds having an inhibitory effect on kinases including Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders that comprise the inhibition of Mixed Lineage Kinases.

DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE

The invention relates to diazaindole derivatives represented by the general formula (I): where A, E, G, R1, R2, R3 and R4 are defined herein, or pharmaceutically acceptable salts thereof, their use in the inhibition of c-Jun N-terminal kinase (JNK) activity, their use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases, autoimmune diseases and/or organ failure. The invention also provides processes for the manufacture of said diazaindole derivatives and compositions containing them.

MLK INHIBITORS AND METHODS OF USE

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

FUSED RING HETEROCYCLE KINASE MODULATORS

The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.